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Abstract
Overexpression of alpha-synuclein (a-SYN), a protein which plays an important role in the pathogenesis of Parkin-
son’s disease (PD), triggers microglial activation and adaptive immune responses, and leads to neurodegeneration
of dopaminergic (DA) neurons. We hypothesized a link between the humoral adaptive immune response and
microglial activation in a-SYN induced neurodegeneration. To test this hypothesis, we employed adeno-associated
virus serotype 2 (AAV2) to selectively over-express human a-SYN in the substantia nigra (SN) of wild-type mice and
FcgR-/- mice, which lack high-affinity receptors for IgG. We found that in wild-type mice, a-SYN induced the
expression of NF-B p65 and pro-inflammatory molecules. In FcgR-/- mice, NF-B activation was blocked and pro-
inflammatory signaling was reduced. Microglial activation was examined using immunohistochemistry for
gp91PHOX. At four weeks, microglia were strongly activated in wild-type mice, while microglial activation was atte-
nuated in FcgR-/- mice. Dopaminergic neurodegeneration was examined using immunohistochemistry for tyrosine
hydroxylase (TH) and unbiased stereology. a-SYN overexpression led to the appearance of dysmorphic neurites,
and a loss of DA neurons in the SN in wild-type animals, while FcgR-/- mice did not exhibit neuritic change and
were protected from a-SYN-induced neurodegeneration 24 weeks after injection. Our results suggest that the
humoral adaptive immune response triggered by excess a-SYN plays a causative role in microglial activation
through IgG-FcgR interaction. This involves NF-B signaling, and leads to DA neurodegeneration. Therefore, block-
ing either FcgR signaling or specific intracellular signal transduction events downstream of FcgR-IgG interaction,
such as NF-B activation, may be viable therapeutic strategies in PD.
Background
Parkinson’s disease (PD) is a neurodegenerative disease
characterized primarily by loss of dopaminergic (DA)
neurons in the substantia nigra (SN) of the midbrain.
The protein alpha-synuclein (a-SYN) is closely linked to
the pathogenesis of PD: genetic mutations or multiplica-
tion of the gene coding a-SYN, SNCA, cause familial
forms of PD, while a-SYN is the main component of
the protein aggregates, Lewy bodies and Lewy neurites
found in sporadic PD [1-4]. Despite the abundant evi-
d e n c ef o rt h er o l eo fa-SYN in the pathogenesis of PD,
the mechanism by which excess a-SYN leads to neuro-
degeneration is still unknown.
Neuroinflammation is a constant feature of PD.
Microglial activation is observed in the SN of PD
patients [5] and there is a correlation between the extent
of microglial activation in the SN and the degree of a-
SYN accumulation [6]. In neurotoxin-induced animal
models of PD, microglia are strongly activated after the
administration of MPTP, rotenone or 6-OHDA [7-10],
and inhibition of microglial activation in these models
attenuates the toxin-related DA neurodegeneration
[11,12]. While cell death is a prominent component of
the toxin-mediated models of PD, it is not a necessary
antecedent of inflammation. Our previous studies in a
mouse model in which a-SYN expression is driven by
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revealed that overexpression of human a-SYN leads to
IgG deposition, classical microglial activation with
increased production of pro-inflammatory cytokines,
and B and T-lymphocyte infiltration in the SN long
before overt neurodegeneration is apparent [13].
An important link between the innate immune sys-
t e mo ft h eb r a i na n dt h ea d a p t i v ei m m u n es y s t e m ,
mediated by circulating B and T cells, is the family of
Fc gamma receptors (FcgR). They are present on the
surface of microglia as well as other cell types, includ-
ing natural killer cells, neutrophils, and mast cells. Fcg
receptors bind immunoglobulin G (IgG) and trigger
signal transduction events leading to microglial activa-
tion [14]. There is indirect evidence for the importance
of Fcg receptors in PD: in postmortem human brain,
PD is associated with increased binding of IgG to DA
neurons in SN and elevated levels of FcgR on microglia
[15]; FcgRI-dependent microglial responses to IgG
from PD patients have been demonstrated in vitro
[16]; and loss of DA neurons is observed in the SN of
rodents following injection of IgG purified from the
sera of PD patients, a process which is also FcgR
dependent [17,18].
Major downstream mediators of FcgRa c t i v a t i o na r e
the NF-B class of transcription factors, which are
important for the regulation of immune and inflamma-
tory responses [19]. They are homo- or heterodimers
composed of members of the NF-B/Rel family, which
include RelA (p65), RelB, cRel, p50 and p52 [20]. Pro-
moter regions of many of the pro-inflammatory cyto-
kines, which are elevated in neurodegenerative
conditions, contain DNA binding sites for NF-B family
proteins, and the inhibition of NF-B activation reduces
the induction of pro-inflammatory molecules [21]. In
human PD brain, there is evidence for increased expres-
sion and nuclear translocation of NF-Bp 6 5p r o t e i n ,
and similar findings are seen in MPTP-intoxicated mice
[22]. In the MPTP mouse model, injection of NEMO-
binding domain (NBD) peptide, which inhibits NF-B
activation, suppresses microglial activation and cytokine
production, and improves motor outcomes [22].
We hypothesized a critical role of microglial FcgR
proteins in linking the humoral arm of the adaptive
immune response to microglial activation and NF-B
signaling in a-SYN induced neuro-degeneration. To
test this hypothesis, we used adeno-associated virus
serotype 2 (AAV2) to selectively over-express human
a-SYN in the substantia nigra (SN) of wild-type mice
and in mice that lack the high-affinity receptors for
immunoglobulin G (FcgR-/- mice), and examined the
role of these receptors in coupling to neuroinflamma-
tion and neurodegeneration.
Methods
Animals and Treatment
Male C57BL/6 mice (8-12 weeks old) were used for the
study. The FcgR-/- mice from C57BL/6 background
were obtained from Taconic labs (model # 000583-M-
M, Taconic, Hudson, NY, USA). These mice (nomen-
clature: B6.129P2-Fcer1g
tm1RavN12) are deficient in the
gamma chain subunit of the FcgRI, FcgRIII and FcεRI
receptors. They exhibit immune system defects such as
inability to phagocytose antibody-coated particles, and
the inflammatory responses to immune complexes are
attenuated [23]. The AAV2 plasmids as well as the
helper plasmid pDG-1 (a kind gift from Dr. Ponnazha-
gan, University of Alabama at Birmingham) were puri-
fied using cesium chloride density gradient
ultracentrifugation. Recombinant AAV2, containing the
gene for human a-SYN (AAV2-SYN) or green fluores-
cent protein (AAV2-GFP) was packaged by co-trans-
fecting AAV2-SYN/GFP plasmids and pDG-1 into
HEK-293 cells using a protocol previously described
[24]. AAV2-SYN and AAV2-GFP were purified by a
single step column purification protocol using heparin
agarose columns [25]. Under isoflurane anesthesia, the
mice were injected stereotaxically with 2 μlo fA A V 2 -
SYN (6.0 × 10
10 viral genome/ml) or AAV2-GFP (2.65
×1 0
11 v i r a lg e n o m e / m l )i n t ot h er i g h tS N ;c o - o r d i -
nates were anterior-posterior, -3.2 mm from bregma,
medio-lateral, -1.2 from midline and dorso-ventral,
-4.6 from the dura.
Immunohistochemistry
Animals were sacrificed at 2 weeks, 4 weeks and 24
weeks following AAV2-SYN or AAV2-GFP injection
and brain tissue was processed for immunohistochem-
istry. In the 2 and 4-week treatment groups, for exam-
ining NF-B activation, we used anti-NF-Bp 6 5a n d
anti-NF-B p50 antibodies. For examining microglial
activation, we used the marker gp91PHOX (a subunit
of the enzyme NADPH-oxidase). For cell type identifi-
cation, we used anti-CD68 antibody to detect micro-
glia. Free-floating SN tissue sections (40μm thick) were
incubated with rabbit anti-human-a-SYN (1:1000, Bio-
source, Camarillo, CA), rabbit anti-green fluorescent
protein (1:1000, Abcam, Cambridge, MA), mouse anti-
NF-B p65 (1:100 Santa Cruz Biotechnology, Santa
Cruz, CA), mouse anti-gp91PHOX (1:1000 AbD Sero-
tec, Oxford, UK), rat anti-CD68 (1:500 Abcam, Cam-
bridge, MA) or mouse anti-green fluorescent protein
(1:500 Millipore, Billerica, MA), rabbit anti-NF-Bp 5 0
(1:100 Santa Cruz Biotechnology, Santa Cruz, CA)
antibodies followed by 1:500 dilution of alexa-488 con-
jugated goat anti-rabbit or anti-rat (Molecular probes,
Carlsbad, CA) and 1:500 dilution of CY3-conjugated
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Grove, PA) antibodies. Since some antibodies were
derived from a mouse host, the sections were first
blocked with a goat anti-mouse F(ab2)f r a g m e n tt op r e -
vent non-specific background staining by the second-
ary antibody.
In the 24-week treatment groups, the mice SN sec-
tions revealed significant autofluorescence and back-
ground staining upon examination with a fluorescence
microscope, which interfered with accurate examination
of the gp91PHOX immunostained microglia. Therefore,
for this time point, we used diaminobenzidine combined
with nickel sulfate intensification to visualize
gp91PHOX positive microglia. Briefly, the SN sections
were stained sequentially, first for gp91PHOX and
developed with diaminobenzidine and nickel sulfate, fol-
lowed by staining for SYN/GFP and developed with only
diaminobenzidine. The primary antibody concentration
was the same as above. The secondary antibodies used
were peroxidase conjugated goat anti-mouse (1:2000,
Jackson Immunoresearch, West Grove, PA) for
gp91PHOX and peroxidase-conjugated goat anti-rabbit
(1:2000, Jackson Immunoresearch, West Grove, PA) for
SYN/GFP. For TH immunostaining, a rabbit polyclonal
primary antibody (Pelfreeze Biologicals, Rogers, AR) was
used at 1:2000 dilution. The secondary antibody used
was a biotinylated goat anti-rabbit (1:4000, Vector Labs,
Burlingame, CA) followed by horseradish peroxidase
conjugated streptavidin (1:1000, Vector Labs, Burlin-
game, CA). The staining was developed using diamino-
benzidine. For the detection of neuritic change, we used
a mouse anti-TH antibody (1:1000, Sigma, St. Louis,
MO) and rabbit anti-green fluorescent protein (1:1000,
Abcam, Cambridge, MA) or rabbit anti-human-a-SYN
(1:1000, Biosource, Camarillo, CA) antibodies followed
by 1:500 dilution of alexa-488 conjugated goat anti-rab-
bit (Molecular probes, Carlsbad, CA) and 1:500 dilution
of CY3-conjugated goat anti-mouse (Jackson Immunore-
search, West Grove, PA) antibodies.
Imaging and Quantification
Confocal images were captured using a Leica TCS-SP5
laser scanning confocal microscope. The images were
processed using the Leica software and exported as
TIFF files and processed using Adobe Photoshop CS2.
For quantitation of NFBp 6 5 ,N F Bp 5 0a n d
gp91PHOX staining, the slides were observed using a
Nikon Eclipse E800 M fluorescent microscope. Coded
slides were scored using a numerical scale from 0 (no
staining) to 4 (most intense) by an observer blind to the
treatment paradigm. Only staining in close proximity to
SN neurons was considered for scoring, while staining
along the needle tract was ignored. Scores obtained
from six mice per group were statistically analyzed using
Mann-Whitney U test.
Isolation of Nuclear Extracts from Midbrain Tissues and
Immunoblotting
Ventral midbrains were frozen immediately on dry ice
and nuclear extracts were obtained using NE-PER®
Nuclear and Cytoplasmic Extraction Reagents (Thermo
Scientific, Rockford, IL). The nuclear extracts were
resolved on 8% sodium dodecyl sulfate polyacrylamide
gel. Proteins were transferred to nitrocellulose mem-
branes incubated with mouse anti-NF-B p65 (1:1000
Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit
anti-NF-B p50 (1:1000 Santa Cruz Biotechnology,
Santa Cruz, CA) antibodies followed by secondary
(1:2000 Jackson Immunoresearch, West Grove, PA) anti-
bodies labeled with horseradish peroxidase. Immunos-
tained bands were detected using ECL kit (Thermo
Scientific, Rockford, IL). Blots were normalized with
lamin (1:1000 Cell Signaling Technology, Danvers, MA)
as appropriate.
Estimation of markers of NF-B activation in the SN using
quantitative PCR
Male C57BL/6 and FcgR-/- mice were injected stereo-
taxically with AAV2-SYN or AAV2-GFP into the right
SN. Two weeks later, the animals were euthanized and
the SN from the injected side was dissected out and
stored at -80°C until assayed by quantitative PCR. Lipo-
polysaccharide (LPS, Sigma, St. Louis, MO) was injected
i n t ot h er i g h tS Na tav o l u m eo f2μla t2 . 5μg/μlc o n -
centration to a separate group of mice as a positive con-
trol. Total RNA from the injected SN was isolated using
the TRI reagent (Sigma, St. Louis, MO) and purified
using the RNeasy mini kit (Qiagen, Valencia, CA). The
RNA was then reverse transcribed into cDNA using a
superscript III kit (Invitrogen, Carlsbad, CA) and cDNA
was measured spectrophotometrically and stored at -20°
C. Primers for the markers were designed using the Pri-
mer3 program http://frodo.wi.mit.edu/. Quantitative-
PCR was performed using a Bio-Rad IQ5 multicolor real
time PCR system. 100 ng/μl of cDNA was used for the
reaction. Serial dilutions of cDNA from LPS injected
mice served as positive control and also as the source of
standard curve from which the values for pro-inflamma-
tory molecules were extrapolated. The expression levels
of the markers examined were normalized against
GAPDH mRNA. Expression ratios were analyzed statis-
tically using one-way ANOVA. We studied markers of
NF-B activation (p65 and p50) as well as a typical mar-
ker for neuroinflammation, intercellular adhesion mole-
cule 1 (ICAM-1). The markers and the primers used are
listed in Table 1.
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TH immunoreactive dopamine neurons were quantified
using unbiased stereology. Briefly, coded slides were
scanned on the stage of a modified Olympus BX51
microbrightfield microscope under low-power objective,
and SN on the injected and un-injected side were con-
toured. TH-positive neurons were counted on both
sides by an optical fractionator method using stereoin-
vestigator 7.0 software from MBF Biosciences (Micro-
brightfield Inc, Williston, VT). A total of 4 sections
covering the rostro-caudal extent of the SN around the
injection site were counted and the number weighted
section thickness was used to correct for variations in
tissue thickness at different sites.
Results
AAV2-mediated overexpression of a-SYN triggers NF-B
activation with accumulation of p65 protein
Groups of 6 of wild-type male C57BL/6 mice were
injected stereotaxically with AAV2-SYN or AAV2-GFP
into the right SN. Over-expression of human a-SYN
resulted in robust expression of NF-Bp 6 5i nm o u s e
SN, while little or no activation was observed in AAV2-
GFP treated mice two weeks after injection (Figure 1A-
D). Examination of a separate set of animals injected
only with PBS vehicle revealed similar low levels of p65
staining (not illustrated). In AAV2-SYN injected mice,
NF-B p65 expression was evident mainly in cells with
the morphology of activated microglia, surrounding the
human a-SYN-expressing neurons in SN, which was
further confirmed by the co-localization of CD68 and
NF-B p65 staining (Figure 1E). For quantification of
NF-B p65 staining, coded slides stained for NF-Bp 6 5
were scored using a numerical scale from 0 (no staining)
to 4 (most intense) by an observer blinded to the treat-
ment paradigm. This analysis confirmed the impression
of markedly enhanced NF-B p65 staining in the
AAV2-SYN injected animals compared to the AAV2-
GFP controls (Figure 1F).
A similar immunohistochemical analysis of the NF-B
p50 protein was performed in these animals. In contrast
to the striking changes in p65, neither the AAV2-SYN
nor the AAV2-GFP vector induced an appreciable
enhancement of p50 staining over baseline (Figure 1G-
J), and the scores assigned by the blinded observer did
not differ significantly between the groups (not
illustrated).
FcgR-/- blocks NF-B activation and p65 accumulation
after AAV2-SYN
To study the role of FcgR in the activation of NF-Bb y
AAV2-SYN, we treated mice with unilateral injections
of either AAV2-SYN or AAV2-GFP into the right SN. A
matched group of male FcgR-/- mice and male wild-type
controls (n = 4-5 in each treatment group) were studied
four weeks after injection. In these animals, we observed
that the expression of the a-SYN and GFP transgenes
induced by the AAV2 vectors was similar in the FcgR-/-
mice and the wild type mice. In the WT mice, there
was strong activation of NF-B p65 at 4 weeks, similar
to that seen at 2 weeks in the previous experiment.
Nevertheless, there was a striking difference in the
expression of NF-Bp 6 5i nt h eF c gR-/- mice injected
with the AAV2-SYN vector. In contrast to the vigorous
staining observed in the wild-type animals, AAV2-SYN
treatment of the FcgR-/- mice produced no apparent
accumulation of p65 (Figure 2A-H). This impression
was confirmed by statistical analysis of p65 scoring per-
formed by the blinded observer (Figure 2I).
To assess accurately the nuclear accumulation of NF-
B components, immunoblotting was performed with
nuclear extracts of the midbrains from different treat-
ment groups. In wild-type groups, there was significant
increase of nuclear NF-B p65 in AAV2-SYN treated
mice compared with AAV2-GFP mice (Figure 2J). The
FcgR-/- groups showed much higher baseline levels of
nuclear NF-B p65 than WT groups, however, within
FcgR-/- groups, over-expresssion of human a-SYN did
not lead to any further increase in NF-B p65 activation
compared with AAV2-GFP treated FcgR-/- controls
(Figure 2J). For nuclear NF-Bp 5 0l e v e l s ,t h e r ew a sn o
difference between AAV2-GFP and AAV2-SYN mice
both in WT and FcgR-/- groups (not illustrated).
FcgR-/- blocks transcriptional induction of NF-B
components and ICAM-1 after AAV2-SYN
The effects of FcgR deletion on the transcription of NF-
B components and the inflammatory mediator ICAM-
1 was examined in a separate group of experimental ani-
mals, and since our previous studies had shown ICAM-1
activation at 2 weeks after AAV2-SYN administration
[13], we used this earlier time point for these mRNA
analysis. Groups of 6 of WT or FcgR-/- mice were
injected stereotaxically with AAV2-SYN or AAV2-GFP
into the right SN. The brain tissue was processed for
quantitative PCR (QPCR). All values were normalized
against glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA measured in the same samples.
Table 1 Markers of NF-B activation and their primers
used for quantitative PCR
Markers Forward Primer Reverse Primer
NF-B p65 GCGTACACATTCTGGGGAGT GTTAATGCTCCTGCGAAAGC
NF-B p50 CACCTAGCTGCCAAAGAAGG GCAGGCTATTGCTCATCACA
ICAM-1 CAGCTACCATCCCAAAGCTC CTTCAGAGGCAGGAAACAGG
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p50 mRNAs. In the wild-type mice, we observed that
overexpression of human a-SYN resulted in elevated
abundance of both NFBp 6 5a n dp 5 0m R N Ai nt h e
SN compared with wild-type AAV2-GFP treated mice.
In contrast, the mRNA level of NFBp 6 5w a s
decreased, rather than increased, in the FcgR-/- SYN
mice compared with FcgR-/- GFP mice. In addition,
there was trend towards reduction of NFBp 5 0
mRNA in FcgR-/- SYN mice compared to FcgR-/- GFP
mice, which did not reach statistical significance (Fig-
ure 3A and 3B).
Figure 1 Effect of over-expression of human a-SYN on NF-B activation in the mouse SN at two weeks. AAV2-SYN and AAV2-GFP
(control) were injected into the right SN, and the tissue was processed for p65 and p50 staining at 2 weeks post-injection. A-D) The AAV2-SYN-
injected SN displayed increased staining for p65 (red), mostly within microglia in close proximity to a-SYN-expressing neurons (green) while no
induction of p65 was seen after AAV2-GFP. E) The staining for p65 (red) co-localized with the staining for CD68 (green), a marker for activated
microglia, showing that NF-B activation occurs in microglia. F) Scoring of immunostaining for p65 on a scale of 0 to 4. Compared with AAV2-
GFP-injected tissues, AAV2-SYN treatment caused a significant increase in NF-B p65. *p < 0.05 using Mann-Whitney U test (n = 6 per group). G-
J) No significant difference was observed in NF-B p50 immunoreactivity between AAV2-GFP and AAV2-SYN treated groups. Scale bars: panels A,
B bar = 40 μm; panel E bar = 5 μm; panels G, H bar = 60 μm; panels C, D, I, J bar = 20 μm.
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Page 5 of 12Figure 2 Effect of a-SYN over-expression on NF-B activation in wild-type and FcgR-/- mice at four weeks. A-H) SN sections of wild-type
and FcgR-/- mice over-expressing human a-SYN or GFP were double stained for NF-B p65 (red) and SYN/GFP (green). Wild-type mice
expressing human a-SYN revealed significantly increased immunoreactivity for NF-B p65 while no significant enhancement of p65 was
observed in FcgR-/- mice. Scale bars: panels A, B, C, D bar = 60 μm; panels E, F, G, H bar = 20 μm. I) Scoring of immunostaining for p65 using a
rating scale revealed significant elevated p65 expression in wild-type mice treated with AAV2-SYN compared to AAV2-GFP group. This difference
was not observed in FcgR-/- mice expressing SYN or GFP. *p < 0.05, WT-SYN vs WT-GFP, Mann-Whitney U test. J) Immunoblotting and
quantification for nuclear NF-B p65 in WT and FcgR-/- mice. In WT mice, AAV2-SYN treated mice showed significant increase in nuclear p65
level compared with AAV2-GFP controls. No difference was observed between FcgR-/- mice expressing a-SYN or GFP, but FcgR-/- mice have
higher baseline levels of nuclear p65 than WT mice. *p < 0.05, WT-SYN vs WT-GFP t-test (N: untreated mice; G: AAV2-GFP mice; S: AAV2-SYN
mice).
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inflammatory mediators, we studied the abundance of
the mRNA for intercellular adhesion molecule 1
(ICAM-1), which contains a consensus sequence for
binding of NF-B p65 [26]. We had previously observed
that ICAM-1 was increased by AAV2-SYN at both 2
weeks and 4 weeks post-injection in wild-type mice [13].
In these experiments we confirmed the effect of AAV2-
SYN on ICAM-1 mRNA levels in wild-type mice, which
led to a more than two fold induction. In contrast, we
observed no evidence for the activation of ICAM-1 tran-
scription in the FcgR-/- mice, with similar levels of
ICAM-1 mRNA in both FcgR-/- GFP and FcgR-/- SYN
groups (Figure 3C).
Microglial activation is attenuated in FcgR-/- mice
Microglial activation was examined at four and twenty-
four weeks following AAV2-SYN or AAV2-GFP admin-
istration using gp91PHOX as a marker [27]. At four
weeks post-injection, we noticed a significant increase in
gp91PHOX immunoreactivity in the wild-type animals
treated with AAV2-SYN compared to those treated with
AAV2-GFP (Figure 4). In a-SYN-expressing wild-type
mice, activated microglia were noticed predominantly
on the injected side. These cells were distributed rostro-
caudally from the injection site close to the SN and also
seen in the surrounding areas. In the FcgR-/- mice,
neither the AAV2-SYN nor the AAV2-GFP induced any
appreciable increase in gp91PHOX immunoreactivity
except for some staining of gp91PHOX along the needle
tract present in all the groups; this was presumed to be
r e l a t e dt ol o c a lt r a u m aa n dw a sn o tc o n s i d e r e df o r
quantification.
I nt h e2 4 - w e e kg r o u p s ,w eu s ead i f f e r e n ts t a i n i n g
method because of the intrinsic autofluoresence present
in older animals. This method is less sensitive than the
fluorescent method used at the earlier time point, and
thus the data from the 24 week observations are not
directly comparable to those obtained at the earlier time
points. We found that after 24w e e k s ,t h ei n t e n s i t yo f
gp91PHOX staining microglia was modest and similar
in AAV2-SYN injected wild-type mice as well as FcgR-/-
mice. There was a trend towards increased gp91PHOX
positive microglia in both wild-type mice and FcgR-/-
mice treated with AAV2-SYN compared to their AAV2-
GFP treated counterparts, but the difference in
gp91PHOX between SYN and GFP groups was not sta-
tistically significant.
a-SYN-induced dopaminergic neurodegeneration is
attenuated in FcgR-/- mice
To examine the effect of FcgR deficiency on a-SYN-
induced neurodegeneration, we examined animals 24
weeks following AAV2-SYN or AAV2-GFP administra-
tion. Sequential sections through the midbrain were
stained for tyrosine hydroxylase (TH) and the TH-posi-
tive dopamine neurons were quantified using unbiased
stereology.
Visual examination revealed a consistent pattern of
loss of TH immunoreactive neurons in the injected side
compared to the non-injected side in wild-type mice
Figure 3 Effect of a-SYN over-expression on the transcription
of NF-B components and the pro-inflammatory mediator in
wild-type and FcgR-/- mice at two weeks. There was significant
increase in the mRNA level of A) NF-B p65, B) NF-B p50, C)
intercellular adhesion molecule 1(ICAM-1) in the WT SYN group
compared to the WT GFP group. **p < 0.01, *p < 0.05 WT GFP vs
WT SYN; and the mRNA level of NFB p65 was decreased in FcgR-/-
SYN mice compared with FcgR-/- GFP mice. **p < 0.01 FcgR-/- SYN
vs FcgR-/- GFP. One-way ANOVA with Fisher PLSD post hoc test,
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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groups (Figure 5A-D). In the wild-type mice treated with
AAV2-SYN, many neurons presented with very weak
immunostaining for TH, and degenerating neurites were
apparent, characterized by beading and loss of TH stain-
ing even when strong TH staining was still evident in the
cell body (Figure 5F-H). Stereological analysis revealed a
27% reduction in the number of TH-positive neurons on
the injected side compared to the contralateral side in
the wild-type AAV2-SYN treated mice (P < .03).
In contrast, the administration of AAV2-SYN to
FcgR-/- mice resulted in no apparent loss of TH stain-
ing, and no degenerating neurites were appreciated (Fig-
ure 5I-K). Quantitative analysis with stereology revealed
no significant reduction in TH-positive neuronal count
in FcgR-/- mice expressing a-SYN compared to those
expressing GFP (Figure 5E).
Discussion
In these studies, we have found that AAV2-mediated
over-expression of human a-SYN in mouse SN triggers
NF-B activation, with transcriptional induction of the
p 6 5a n dp 5 0c o m p o n e n t s ,a sw e l la si n d u c t i o no ft h e
pro-inflammatory mediator ICAM-1. There is microglial
activation and marked accumulation of p65 protein in
microglia. Deficiency of FcgR blocks the transcriptional
induction of p65, p50, and ICAM-1, prevents microglial
p65 accumulation. Moreover, a-SYN-induced microglial
activation and dopaminergic neurodegeneration are atte-
nuated in FcgR-/- mice.
We employed an AAV2 mouse model of Parkinson’s
disease in our study, which we have characterized pre-
viously [13]. Vector strategies provide both targeted
delivery and high levels of transgene expression. The
AAV vector encodes no viral proteins, and the vector
itself has little or no immunogenicity or toxicity; indeed,
we observed no significant immunological activation in
our control animals, despite strong expression of the
encoded GFP protein. In the mouse AAV model, micro-
glial activation and neuroinflammation are early events,
while loss of dopaminergic neurons occurs later, after
more than 3 months [28]. This profile differs from
Figure 4 Effect of a-SYN over-expression on microglial activation in wild-type and FcgR-/- mice. A-D) At four weeks after AAV injection,
SN sections of wild-type and FcgR-/- mice over-expressing a-SYN or GFP were double-stained for gp91PHOX (red) and SYN/GFP (green). Wild-
type mice expressing a-SYN revealed significantly increased immunoreactivity for gp91PHOX compared to the other three groups. gp91PHOX
immunoreactivity was localized to microglia, which appear to be close to a-SYN-expressing neurons (scale bar = 50 μm). E) Scoring of microglial
activation using a rating scale revealed significant microglial activation in wild-type mice expressing a-SYN compared to those expressing GFP.
This difference was not observed in FcgR-/- mice expressing SYN or GFP. *p < 0.05, WT-SYN vs WT-GFP, Mann-Whitney U test.
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Page 8 of 12Figure 5 Effect of a-SYN over-expression on dopaminergic neurodegeneration in wild-type and FcgR-/- mice. A-D) The SN of wild-type
and FcgR-/- mice expressing a-SYN or GFP was stained for tyrosine hydroxylase 24 weeks after treatment. The images depict a representative
sample of the injected side of the SN of the four treatment groups. E) Counts of TH positive neurons using unbiased stereology. The wild-type
mice treated with AAV2-SYN revealed a significant reduction in dopamine neuron count in the injected side compared to the un-injected side.
No significant loss of dopamine neurons was observed in wild-type mice treated with AAV2-GFP and FcgR-/- mice expressing GFP/SYN. *p <
0.05, one-tailed t test, ipsilateral vs contralateral in WT SYN mice. F-K) Representative neurite samples of WT AAV2-SYN and FcgR-/- AAV2-SYN
mice. The a-SYN(green)-expressing neuron in WT mice has little TH (red) staining in the beaded degenerating neurite, while FcgR-/- mice are
protected from neuritic change. Panel H and K are high-magnification images of the neurites in the square of panel G and J respectively. Scale
bars: panels A, B, C, D bar = 200 μm; panels F, G, I, J bar = 25 μm; panels H, K bar = 6 um.
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Page 9 of 12similar AAV models in rats, where the degenerative pro-
cess appears to be more rapid [29]. Both of these AAV-
mediated approaches replicate the dopaminergic neuro-
degeneration which is the signature characteristic of
human PD. Transgenic animals expressing a-SYN, in
contrast, rarely show dopaminergic cell loss, or only at
very advanced ages [30]. At the other extreme, neuro-
toxin-induced PD models, such as the mouse MPTP
model, lead to rapid necrosis of dopamine neurons with
oxidative damage to DNA, lipids, and proteins [31,32].
There is prominent neuroinflammation after MPTP
treatment, but the relevance of this to the gradual pro-
cess of cell injury in human PD is certainly open to
question.
Our data point to a central role for FcgRp r o t e i n si n
mediating a-SYN-induced neuroinflammation. In the
mouse, the classic FcgRs are well characterized and
include FcgRI, FcgRIIB and FcgRIII. Both FcgRI and
FcgRIII are multi-chain complexes composed of a single
ligand-binding a-chain and a homodimer of common g-
chains that mediates intracellular signaling through an
immuno-receptor tyrosine-based activation motif
(ITAM) in the cytoplasmic domain [33]. The FcgR-/-
mice that we used in our studies are deficient in the g-
chain subunit of the FcgRI and FcgRIII, leading to
approximately 20% of normal levels of FcgRI expression,
and total lack of FcgRIII expression. Thus, our data do
not allow us to distinguish between effects mediated by
FcgRI or FcgRIII, and it is possible that either or both of
them are involved in the a-SYN-induced neuroinflam-
mation. It is also important to note that although the
FcgR-/- mice have been backcrossed to the genetic back-
ground of C57BL/6 mice, they do exhibit immune sys-
tem defects. This likely accounts for the baseline
differences we observed in the expression of NF-B
components and ICAM-1 mRNA in the FcgR-/- mice
compared with wild-type mice (Figure 2 and 3). We also
observed that the FcgR-/- mice had greater baseline
abundance of p65 in the nuclear fraction (Figure 2J),
likely also a consequence of altered immunity in these
animals. Interestingly, they do not appear to have an
increase in cytoplasmic p65 at baseline, as evidenced by
the low level of p65 staining observed using immunohis-
tochemistry (Figure 2C). The significance of this dispar-
ity is uncertain; nuclear p65 is clearly linked to
transcriptional effects, but the potential activities of
cytoplasmic p65 are much less clear. Because of these
baseline disparities between control and FcgR-/-animals,
we have based our conclusions on comparisons of the
results of AAV2-GFP and AAV2-SYN treatment within
the WT or FcgR-/- groups.
In this study, we observed a significant role of NF-B
in a-SYN-induced neuroinflammation and neurodegen-
eration. In unstimulated cells, NF-B is bound by the
inhibitor IB which sequesters NF-B in the cytoplasm.
Activation of NF-B is initiated by the signal-induced
degradation of IB proteins. This occurs primarily via
the activation of IB kinase (IKK), which can phosphor-
ylate IB at two conserved N-terminal Ser residues.
Subsequent ubiquitination and degradation of the inhi-
bitor results in liberation of the heterodimeric NF-B
complexes, which are able to migrate into the nucleus
and to regulate gene expression [20]. In mammals, the
most abundant NF-B complex is p65/p50 [34]. In our
model, we observed increased mRNA for both p65 and
p50, but only the p65 protein exhibited prominent accu-
mulation in microglia. The reason for the relative lack
of accumulation of p50 is uncertain, but it might be
related to differences either in mRNA translation or
protein degradation. It is also possible that in this
model, p65 has partners other than p50, such as p52
[35]. The data on ICAM-1 provide evidence that NF-B
signaling was indeed activated, as this gene is strongly
regulated by the binding of NF-B to an intronic site
[26]. The transcriptional activation of p65 and p50, the
accumulation of p65 protein, and the induction of
ICAM-1 were all attenuated in the FcgR-/- animals.
Our observations also suggest that the lack of FcgR
protein attenuates neurodegeneration and loss of TH-
positive neurons, but it is important to consider this
finding in the context of the limitations of the model
system. In wild-type animals, AAV2-SYN led to the
appearance of degenerating neurites, and these were
greatly reduced in the FcgR-/- animals. To assess the
differences quantitatively, we used unbiased stereology
to count surviving TH-positive neurons in the SN. We
observed loss of TH-positive cells in the wild-type ani-
mals after AAV2-SYN but, as in most rodent a-SYN
models of PD, the degree of loss induced by a-SYN
overexpression was modest (27%) and there was consid-
erable variability (SD = 22). We did not observe loss of
TH cells in the FcgR-/- animals, but the statistical
power of our experiment to detect a reduction in the
size of this already modest effect is limited; a power cal-
culation suggests that the group sizes employed here
provide less than 80% power to detect this degree of cell
loss. Achieving 95% power would require group sizes of
at least 24, a total of nearly 100 animals, which is
impractical. Although the data on TH neuron number
we obtained are consistent with the qualitative assess-
ment of neuritic change and our other observations, we
cannot exclude the possibility of a Type II error and
this particular finding requires further evaluation in
models with more robust baseline neurodegeneration.
The AAV2 model is very different from MPTP neuro-
toxin models of PD, but role of NF-B signaling in the
two types of models is remarkably similar. In MPTP
treated mice, there is also marked accumulation of p65
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Page 10 of 12in microglia, and activation of NF-B was detected
within the SN by electrophoretic mobility shift assay
(EMSA) [22]. Cytokine expression was also increased in
MPTP-intoxicated mice [22]. Injection of NEMO-bind-
ing domain (NBD) peptide, which inhibits NF-B activa-
tion, suppressed microglial activation and cytokine
production, protected both the nigrostriatal axis and
neurotransmitters, and improved motor functions in
MPTP-intoxicated mice [22]. In the AAV model, the
evidence linking NF-B to neurodegeneration is at pre-
sent more circumstantial; we have observed that dele-
tion of FcgRr e d u c e sb o t hN F - B activation and
neurodegeneration, but it does not establish that NF-B
is solely responsible for these effects, and it is possible
that FcgR deletion also alters other signaling pathways.
In this context, studies using pharmacological inhibitors
of NF-B in the AAV model would be very valuable.
Conclusion
In sum, our data provide evidence that FcgRp r o t e i n s
provide an important interface between the adaptive
immune response, specifically the humoral response,
and the neurodegenerative processes triggered by a-
SYN over-expression. The humoral response is gener-
ated by excess a-SYN, although the nature of the speci-
fic antigen is still uncertain. In MPTP neurotoxin
models, there is evidence, which suggests that nitrated
forms of a-SYN may be responsible, but whether this is
also the case in the AAV model (and the human dis-
ease) is unclear. We propose that the binding of this
induced IgG to FcgR on the surface of microglia results
in the downstream signaling pathways, in which NF-B
is the key transcription factor, and causes microglial
activation and cytokine production that ultimately
injures neurons in the SN (Figure 6). This hypothesis
suggests that inhibition of either FcgR signaling or speci-
fic intracellular signal transduction events downstream
of FcgR-IgG interaction, such as NF-B activation, may
be viable therapeutic strategies to slow or prevent the
progression of human PD.
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